Disclaimer

To help you trust the information we provide, every article posted by Hudson Medical relies on peer-reviewed studies and medically reviewed facts. We ensure that data, ideas, and figures cited are reliable, current, and accurate.

Nothing in this article is intended to be prescriptive or medical advice. Talk to your doctor before starting a new diet and exercise plan. Information presented is about our medically supervised weight management programs and is not an advertisement for a specific drug.

Sources

  1. Lim, G. E. & Brubaker, P. L. (2006). Glucagon-Like Peptide 1 Secretion by the L-Cell: The View From Within. Diabetes. 55 (Supplement_2). S70-S77. https://doi.org/10.2337/db06-S020
  2. Ramracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., Clark, A., Johnson, P. R., Rorsman, P., & Briant, L. J. B. (2018). GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca2+ channels. Physiological reports, 6(17), e13852. https://doi.org/10.14814/phy2.13852
  3. Fruh S. M. (2017). Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. Journal of the American Association of Nurse Practitioners, 29(S1), S3–S14. https://doi.org/10.1002/2327-6924.12510
  4. Perez-Montes DE Oca, A., Pellitero, S., & Puig-Domingo, M. (2021). Obesity and GLP-1. Minerva endocrinology, 46(2), 168–176. https://doi.org/10.23736/S2724-6507.20.03369-6
  5. Shah, M., & Vella, A. (2014). Effects of GLP-1 on appetite and weight. Reviews in endocrine & metabolic disorders, 15(3), 181–187. https://doi.org/10.1007/s11154-014-9289-5
  6. Prasad-Reddy, L., & Isaacs, D. (2015). A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in context, 4, 212283. https://doi.org/10.7573/dic.212283
  7. Hira, T., Trakooncharoenvit, A., Taguchi, H., & Hara, H. (2021). Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity. International journal of molecular sciences, 22(12), 6623. https://doi.org/10.3390/ijms22126623
  8. Bodnaruc, A. M., Prud'homme, D., Blanchet, R., & Giroux, I. (2016). Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutrition & metabolism, 13, 92. https://doi.org/10.1186/s12986-016-0153-3
  9. Khalid, W., Arshad, M. S., Jabeen, A., Muhammad Anjum, F., Qaisrani, T. B., & Suleria, H. A. R. (2022). Fiber-enriched botanicals: A therapeutic tool against certain metabolic ailments. Food science & nutrition, 10(10), 3203–3218. https://doi.org/10.1002/fsn3.2920
  10. DiNicolantonio, J. J., & O'Keefe, J. H. (2017). Good Fats versus Bad Fats: A Comparison of Fatty Acids in the Promotion of Insulin Resistance, Inflammation, and Obesity. Missouri medicine, 114(4), 303–307. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140086/
  11. Beysen, C., Karpe, F., Fielding, B. A., Clark, A., Levy, J. C., & Frayn, K. N. (2002). Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia, 45(11), 1533–1541. https://doi.org/10.1007/s00125-002-0964-9
  12. U.S. Food & Drug Administration. (2022, March 7). Health Claim Notification for Saturated Fat, Cholesterol, and Trans Fat, and Reduced Risk of Heart Disease. https://www.fda.gov/food/food-labeling-nutrition/health-claim-notification-saturated-fat-cholesterol-and-trans-fat-and-reduced-risk-heart-disease
  13. Li, Y., Wu, Y., Wu, L., Qin, L., & Liu, T. (2022). The effects of probiotic administration on patients with prediabetes: a meta-analysis and systematic review. Journal of translational medicine, 20(1), 498. https://doi.org/10.1186/s12967-022-03695-y
  14. Dimidi, E., Cox, S. R., Rossi, M., & Whelan, K. (2019). Fermented Foods: Definitions and Characteristics, Impact on the Gut Microbiota and Effects on Gastrointestinal Health and Disease. Nutrients, 11(8), 1806. https://doi.org/10.3390/nu11081806
  15. Rippe, J. M., & Angelopoulos, T. J. (2016). Relationship between Added Sugars Consumption and Chronic Disease Risk Factors: Current Understanding. Nutrients, 8(11), 697.
  16. Jones, S., Luo, S., Dorton, H. M., Yunker, A. G., Angelo, B., Defendis, A., Monterosso, J. R., & Page, K. A. (2021). Obesity and Dietary Added Sugar Interact to Affect Postprandial GLP-1 and Its Relationship to Striatal Responses to Food Cues and Feeding Behavior. Frontiers in endocrinology, 12, 638504. https://doi.org/10.3389/fendo.2021.638504
  17. Neag, M. A., Mocan, A., Echeverría, J., Pop, R. M., Bocsan, C. I., Crişan, G., & Buzoianu, A. D. (2018). Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Frontiers in pharmacology, 9, 557. https://doi.org/10.3389/fphar.2018.00557
  18. Yu, Y., Hao, G., Zhang, Q., Hua, W., Wang, M., Zhou, W., Zong, S., Huang, M., & Wen, X. (2015). Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochemical pharmacology, 97(2), 173–177. https://doi.org/10.1016/j.bcp.2015.07.012
  19. Yaribeygi, H., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2021). Boosting GLP-1 by Natural Products. Advances in experimental medicine and biology, 1328, 513–522. https://doi.org/10.1007/978-3-030-73234-9_36
  20. Wijekoon, C., Netticadan, T., Siow, Y. L., Sabra, A., Yu, L., Raj, P., & Prashar, S. (2022). Potential Associations among Bioactive Molecules, Antioxidant Activity and Resveratrol Production in Vitis vinifera Fruits of North America. Molecules (Basel, Switzerland), 27(2), 336.
  21. Li, Z., Wang, Y., Xu, Q., Ma, J., Li, X., Yan, J., Tian, Y., Wen, Y., & Chen, T. (2023). Berberine and health outcomes: An umbrella review. Phytotherapy research : PTR, 37(5), 2051–2066. https://doi.org/10.1002/ptr.7806
  22. Sharifi-Rad, J., Rayess, Y. E., Rizk, A. A., Sadaka, C., Zgheib, R., Zam, W., Sestito, S., Rapposelli, S., Neffe-Skocińska, K., Zielińska, D., Salehi, B., Setzer, W. N., Dosoky, N. S., Taheri, Y., El Beyrouthy, M., Martorell, M., Ostrander, E. A., Suleria, H. A. R., Cho, W. C., Maroyi, A., … Martins, N. (2020). Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Frontiers in pharmacology, 11, 01021. https://doi.org/10.3389/fphar.2020.01021
  23. Kim, T. W., Jeong, J. H., & Hong, S. C. (2015). The impact of sleep and circadian disturbance on hormones and metabolism. International journal of endocrinology, 2015, 591729. https://doi.org/10.1155/2015/591729
  24. Chaput, J. P., Dutil, C., Featherstone, R., Ross, R., Giangregorio, L., Saunders, T. J., Janssen, I., Poitras, V. J., Kho, M. E., Ross-White, A., & Carrier, J. (2020). Sleep duration and health in adults: an overview of systematic reviews. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 45(10 (Suppl. 2)), S218–S231. https://doi.org/10.1139/apnm-2020-0034
  25. Hamasaki H. (2018). Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?. World journal of diabetes, 9(8), 138–140. https://doi.org/10.4239/wjd.v9.i8.138
  26. Siddiqui, N. I., Nessa, A., & Hossain, M. A. (2010). Regular physical exercise: way to healthy life. Mymensingh medical journal : MMJ, 19(1), 154–158. https://pubmed.ncbi.nlm.nih.gov/20046192/#:~
  27. Schernthaner-Reiter, M. H., Wolf, P., Vila, G., & Luger, A. (2021). The Interaction of Insulin and Pituitary Hormone Syndromes. Frontiers in endocrinology, 12, 626427. https://doi.org/10.3389/fendo.2021.626427
  28. Collins, L. & Costello, R. A. (2023). Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK551568/
  29. U.S. Food & Drug Administration. (2022, June 29). Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

What You Need to Know About Tirzepatide Weight Loss Results